Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Trimming Jobs Amid Europe Business Rejig

Executive Summary

The rumor mill has it that Cipla has begun a significant personnel "rightsizing" effort as it tweaks its business strategy for the next phase of growth. The Indian firm maintains that any job cuts are from natural attrition from its evolving business model in Europe.

You may also be interested in...



Job Cuts Seen At Dr Reddy’s Amid Cost Recalibration

Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and more nimble. Headcount rationalization in R&D is rumored to be already underway, while more operational areas could potentially see significant manpower reductions.

Cipla Sees Changed Profile; Wraps Up Europe Revamp

Cipla's management sees the firm's profile changing as it scales up its US business with new launches and a step-up in product filing intensity. The Indian company is also "largely done" with a restructuring in Europe that saw a significant cutback in personnel but is expected to make the European business profit-accretive.

Cipla's CEO Departs Amid "Text-Book" Succession Plan For Future

Cipla has announced the departure of its CEO Subhanu Saxena and the elevation of a promoter family member, Samina Vaziralli, as it transitions to its next phase of growth. Vaziralli's elevation reinforces the long-term commitment of the promoter group to Cipla and comes amid on-and-off speculation that the company may be a sell-off candidate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel